TICKERNERD
Menu
SGMTSGMTHealthcare · Biotechnology

SGMT Stock Forecast: Sagimet Biosciences, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$9.16
−2.29% on the day

The 12 Wall Street analysts covering Sagimet Biosciences, Inc. hold a median 12-month price target of $27 — +194.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 2 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$568.1M
Ticker Nerd rank
37 / 100
Median analyst target
$27
Analysts covering
12
Revenue$0.0
Operating income−$15.8M
Net income−$14.0M
Free cash flow−$11.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.9%
1M
−16.7%
YTD
+54.6%
1Y
+27.9%
From 52W high
−18.0%
From 52W low
+101.2%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SGMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sagimet Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Oct 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
79
Growth
73
Value
54
Quality
52
Size
52
Revisions
43
Accruals
22
Issuance
17
Volatility
16

Momentum (79): The shares have been drifting up relative to others.

Volatility (16): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26SGMTHigh $56Median $27Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy0 Hold1 Sell
Low $7Median $27High $56

The green dot is the last close — the median target sits +194.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
24 Sept 2026Goldman SachsReinstatesSell$7.00
9 Sept 2026BarclaysUpgradeOverweight—
9 Sept 2026BarclaysUpgradeOverweight$8.00 → $18
9 Sept 2026Cantor FitzgeraldInitiatesOverweight—
9 Sept 2026Cantor FitzgeraldInitiatesOverweight$11
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$29
25 Aug 2026HC Wainwright & Co.ReiteratesBuy—
14 Aug 2026CitizensMaintainsMarket Outperform—
14 Aug 2026CitizensMaintainsMarket Outperform$12 → $29
12 Aug 2026Canaccord GenuityMaintainsBuy$49 → $56
12 Aug 2026Canaccord GenuityMaintainsBuy—
19 May 2026CitizensMaintainsMarket Outperform$35 → $12
19 May 2026CitizensMaintainsMarket Outperform—
4 May 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026GuggenheimMaintainsBuy—
11 Mar 2026HC Wainwright & Co.ReiteratesBuy—
3 Feb 2026GuggenheimInitiatesBuy—
3 Feb 2026HC Wainwright & Co.ReiteratesBuy—
28 Jan 2026BarclaysInitiatesEqual-Weight—
14 Nov 2025CitizensMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SGMT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Sagimet Biosciences, Inc. returned +27.9% against +16.2% for the S&P 500, dividends included.

SGMT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26SGMTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
3
Fundamentals

Sagimet Biosciences, Inc. (SGMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.8×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 41% of US stocks

EV / EBITDA
−5.8×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−24.4%

Higher than 30% of US stocks

Return on assets
−16.4%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sagimet Biosciences, Inc. (SGMT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sagimet Biosciences, Inc. has a market value of $568.1M and an enterprise value of $329.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$47.1M.

  • Diluted earnings per share, trailing twelve months: $−1.28.

  • Free cash flow in the twelve months to 30 June 2026: −$41.7M.

  • Shares outstanding: 61.8M.

  • Trailing P/E: −5.8×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sagimet Biosciences, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Oct 2026

Data provided by Twelve Data

Peers

SGMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SGMTSagimet Biosciences, Inc.$568.1M
37
CRMDCorMedix, Inc.$560.4M
58
CTMXCytomX Therapeutics, Inc.$553.4M
48
MPLTMapLight Therapeutics, Inc.$545.8M
11
YDESYD Bio Ltd.$574.5M
2
PHATPhathom Pharmaceuticals, Inc.$541.8M
74
PRMEPrime Medicine, Inc.$540.5M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sagimet Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGMT news & analysis

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

GlobeNewsWire · 1 Oct 2026neutral

Sagimet Biosciences announced the closing of its previously announced underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share, along with pre-funded warrants to purchase 2,750,010 shares at $9.9999 per warrant for certain investors.

Why it matters — The closing of this offering provides Sagimet with additional capital, which is relevant to SGMT watchers monitoring the company's funding and share structure.

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

Seeking Alpha · 30 Sept 2026neutral

Sagimet Biosciences discussed 52-week Phase 3 data and its U.S. Phase 3 plans for denifanstat in treating moderate to severe acne, according to a Seeking Alpha transcript of the company's presentation.

Why it matters — SGMT watchers would care because this provides an update on denifanstat's clinical progress and the company's roadmap for its U.S. Phase 3 program in moderate to severe acne.

Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise

Benzinga · 30 Sept 2026positive

Sagimet Biosciences reported 52-week data from a Phase 3 trial of denifanstat for moderate to severe acne vulgaris, and the company also completed a capital raise during the period.

Why it matters — The positive acne clinical data and successful capital raise are notable developments for Sagimet's pipeline funding and its progress in the dermatology indication.

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

GlobeNewsWire · 30 Sept 2026neutral

Sagimet Biosciences announced the pricing of an underwritten offering of Series A common stock and pre-funded warrants expected to raise approximately $115.0 million in gross proceeds. The offering, selling 8,750,010 shares at $10.00 per share plus pre-funded warrants, is expected to close on or about October 1, 2026.

Why it matters — SGMT watchers would care because this capital raise provides funding for the clinical-stage biopharmaceutical company's operations, though it also results in share dilution for existing investors.

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

GlobeNewsWire · 30 Sept 2026positive

Sagimet announced positive full 52-week results from license partner Ascletis' Phase 3 open-label extension trial of denifanstat in patients with moderate to severe acne, presented at EADV 2026. The drug showed progressive improvements across efficacy endpoints, including response rates on Investigator's Global Assessment and reductions in total and inflammatory lesions, and was generally well-tolerated.

Why it matters — SGMT watchers would care because these favorable late-stage data for denifanstat from a partner study, along with upcoming U.S. Phase 3 screening and a September KOL event, support progress in the company's lead candidate's development.

FAQ

Frequently asked questions about SGMT stock

What is the SGMT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Sagimet Biosciences, Inc. have a median 12-month price target of $27, with estimates ranging from $7 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGMT stock a buy right now?

Of the 12 analysts covering Sagimet Biosciences, Inc., 11 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sagimet Biosciences, Inc. 37 out of 100 across roughly 4,600 US stocks as at 2 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGMT?

As at 2 Oct 2026, Sagimet Biosciences, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).

Will SGMT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +194.9% from the last close, and Ticker Nerd's factor model ranks Sagimet Biosciences, Inc. 37 out of 100 as at 2 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGMT stock forecast for 2030?

No analyst covering Sagimet Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $56 over the next 12 months.

How has SGMT stock performed over the past year?

Sagimet Biosciences, Inc. returned +27.9% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sagimet Biosciences, Inc. do?

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases.

What is the latest news on SGMT?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants". Sagimet Biosciences announced the closing of its previously announced underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share, along with pre-funded warrants to purchase 2,750,010 shares at $9.9999 per warrant for certain investors.

Company

About Sagimet Biosciences, Inc.

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis. Its lead assets include oral therapies under development for conditions such as metabolic dysfunction-associated steatohepatitis and related disorders, along with additional research programs in dermatology and oncology. Sagimet operates as a single business segment devoted to drug discovery, clinical development, and eventual commercialization of targeted therapies. The stock is used by investors to gain exposure to a specialty biotechnology company centered on in-house discovered, mechanism-based treatments for diseases with limited therapeutic options.

CEO Mr. David A. Happel · 16 employees · United States · https://www.sagimet.com